Access Bio, Inc. Logo

Access Bio, Inc.

Develops and manufactures rapid diagnostic tests for infectious diseases for global health.

950130 | KO

Overview

Corporate Details

ISIN(s):
KR8840090003
LEI:
Country:
United States of America
Address:
65 Clyde Road Suite A, Somerset NJ
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Access Bio, Inc. is a biotechnology company dedicated to the prevention and early diagnosis of infectious diseases. It engages in the research, development, manufacturing, and marketing of in vitro rapid diagnostic tests (IVD), biosensors, and molecular diagnostic products. The company is a key partner in global health, recognized for its comprehensive portfolio of tests for diseases such as malaria, HIV, HPV, and COVID-19. Through its products, including the CareStart™ line, Access Bio focuses on providing high-quality, accessible diagnostic solutions to combat serious health threats worldwide, particularly in developing nations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-05 00:00
Regulatory News Service
기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내)
Korean 3.2 KB
2025-08-18 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 대상결정 기한 안내 )
Korean 3.0 KB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 2.8 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 3.1 MB
2025-08-14 00:00
Earnings Release
반기또는분기매출액미달사실발생
Korean 6.0 KB
2025-08-14 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 관련)
Korean 3.2 KB
2025-08-14 00:00
Delisting Announcement
주권매매거래정지 (상장적격성 실질심사 대상 (사유발생))
Korean 4.6 KB
2025-05-20 00:00
Remuneration Information
[기재정정]주식매수선택권부여에관한신고
Korean 26.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.9 MB
2025-04-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 88.3 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 28.5 KB
2025-03-26 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.6 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 26.7 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 2.8 MB
2025-03-11 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 15.7 KB

Automate Your Workflow. Get a real-time feed of all Access Bio, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Access Bio, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Access Bio, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Chemomab Therapeutics Ltd. Logo
Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.
United States of America
CMMB
CHINA PHARMA HOLDINGS, INC. Logo
Develops, manufactures, and sells prescription, OTC, and nutritional products for human use.
United States of America
CPHI
China SXT Pharmaceuticals, Inc. Logo
Researches, produces, and sells advanced Traditional Chinese Medicine (TCM) herbal products.
United States of America
SXTC
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea
034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan
4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden
CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America
CING
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway
CRNA
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America
CTOR
Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America
CTXR

Talk to a Data Expert

Have a question? We'll get back to you promptly.